Patient data sets to be major component of RWE Solutions Market by 2023

The global real-world evidence market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3% during the forecast period.

(EMAILWIRE.COM, August 03, 2018 ) Full Report : https://www.marketsandmarkets.com/Market-Reports/real-world-evidence-solution-market-76173991.html 

Objectives of the Study

To define, describe, and forecast the global real-world evidence market on the basis of component, therapeutic area, end user, and region
To provide detailed information regarding the major factors influencing the growth of the real world evidence solutions market (drivers, restraints, opportunities, and industry-specific challenges)
To strategically analyze micromarkets with respect to the individual growth trends, future prospects, and contributions to the overall market
To analyze the opportunities in the real world evidence solutions market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World, along with major countries in these regions
To strategically profile the key players and comprehensively analyze their market shares and core competencies in the real-world evidence market
To track and analyze competitive developments such as partnerships, agreements, & collaborations; alliances; mergers & acquisitions; and new service launches in the global real world evidence solutions market
Press Release : https://www.marketsandmarkets.com/PressReleases/real-world-evidence-solution.asp 

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as D&B Hoovers, Bloomberg Business, and Factiva, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. 

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=76173991

By component, the data sets segment accounted for the largest share of the real world evidence market in 2017.

On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

By end user, the pharmaceutical & medical device companies segment held the largest market share of the real world evidence market in 2017.

Based on end user, the pharmaceutical & medical device companies segment accounted for the largest share of the real world evidence market. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.